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Objectives. To estimate endothelial dysfunction in patients with rheumatoid arthritis (RA) of short duration in relation to disease
activity based on the assessment of 28 joints (DAS28). Methods. We studied 29 patients (22 women, mean age 41 (SD, 9) years)
with RA of short duration and 29 healthy controls. The RA subjects were divided into those with low (DAS28: 2.6–5.1, 𝑛 = 18)
or high (DAS28 > 5.1, 𝑛 = 11) disease activity. Exclusion criteria included clinically overt atherosclerosis and other coexistent
diseases. Biochemical markers of inflammatory activation and endothelial dysfunction were measured. Results. There were no
significant intergroup differences in the majority of classical cardiovascular risk factors. High-sensitivity C-reactive protein, tumor
necrosis factor-𝛼, and interleukin-6were increased in RA subjects. Compared to the controls, levels of soluble vascular cell adhesion
molecule-1, von Willebrand factor, and pentraxin-3 were significantly elevated in RA subjects with low disease activity, exhibiting
no further significant rises in those with high disease activity. Asymmetric dimethyl-L-arginine, soluble E-selectin, monocyte
chemotactic protein-1, and osteoprotegerin were increased only in RA patients with high disease activity.Conclusions. Our findings
might suggest a dissociation of pathways governing generalized and joint-specific inflammatory reactions from those involved in
endothelial activation and inflammation within the vascular wall.
1. Introduction
Patients with early rheumatoid arthritis (RA) exhibit
increased morbidity and mortality due to cardiovascular
(CV) diseases [1]. Increased incidence of CV events in
RA is mainly a consequence of accelerated atherogenesis
[2] that cannot fully be explained by traditional CV risk
factors [3, 4]. Accelerated atherogenesis accompanying RA
is linked to endothelial activation and dysfunction [5] that
has been observed already in patients with early RA [6–8].
Endothelial dysfunction is considered a consequence of a
corollary of multiple interactions including classical CV risk
factors, genetic predisposition and polymorphisms, chronic
inflammation, oxidative stress, and metabolic abnormalities
[2, 9, 10]. Among the above mentioned mechanisms,
elevated inflammatory activity appears a major contributor
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to endothelial dysfunction in patients with RA [11–13].
Proinflammatory cytokines such as tumor necrosis factor
alfa (TNF-𝛼), interleukin 1𝛽 (IL-1𝛽), and interleukin-6 (IL-
6), generated within the inflamed synovium of RA patients,
are released into the systemic circulation and putatively affect
endothelial cells [11]. Endothelial dysfunction/activation is
reflected by high levels of leukocyte adhesionmolecules (e.g.,
vascular cell adhesion molecule-1 (VCAM-1), intercellular
adhesion molecule-1 (ICAM-1), and E-selectin), increased
level of von Willebrand factor (vWf), and a shift towards
prothrombotic activity of the endothelium. Endothelial
dysfunction is largely mediated by reduced nitric oxide
(NO) bioavailability with a probable contribution of
increased levels of asymmetric dimethylarginine (ADMA),
an endogenous inhibitor of NO synthesis.
To the best of our knowledge, the association of endothe-
lial dysfunction with clinical and biochemical indices of
disease severity has not been extensively studied in patients
with RA of short duration so far. Therefore, our goal was
to estimate the magnitude of endothelial dysfunction in
patients with RA of short duration in relation to the degree
of systemic inflammatory activation and the well-recognized
disease activity score based on the assessment of 28 joints
(DAS28).
2. Methods
2.1. Study Population. We studied 29 adult patients (22
women, 7 men, mean (SD) age 41 (9) years), with RA of short
duration recruited from the group of patients with arthri-
tis referred to the Outpatient Rheumatology Clinic of the
Department of Internal Diseases of the University Hospital
in Krakow. The diagnosis of RA was established according
to the revised 1987 American College of Rheumatology
(formerly the American Rheumatism Association) criteria
[14]. The patients have had disease duration of ≥6 weeks,
have not been treated with any biological or non-biological
disease-modifying anti-rheumatic drugs (DMARDs), have
been without any treatment, or have been receiving a stable
dose of non-steroidal anti-inflammatory drugs (NSAIDs)
and/or steroids for at least 4 weeks prior to enrollment in our
study. Treatment withDMARDswas given to all patients with
diagnosis of RA according to current guidelines directly after
completion of the study protocol. For all RA patients, DAS28
including high-sensitivity C-reactive protein (hsCRP), the
tender joint count (28 joints), the swollen joint count (28
joints), and the patient’s assessment of global well-being
(100mm visual analogue scale-VAS) was calculated [15]. We
divided patients with RA according to value of DAS28 into
two groups: with high and low disease activity with a cut-off
point of DAS28 of 5.1, subjects with a DAS28 below 2.6 were
excluded from the calculation.
Additionally, we studied 29 healthy control subjects (13
women, 16 men, with the mean age of 32 (SD, 8) years),
recruited mainly among personnel of our hospital, their
relatives, and friends.
Exclusion criteria—common for both groups—
included clinical evidence of atherosclerotic CV disease
(i.e., coronary artery disease, history of acute coronary
syndrome, stroke/transient ischemic attack, peripheral
artery disease, and symptomatic carotid artery stenosis),
uncontrolled/untreated hypertension, diabetes, an estimated
glomerular filtration rate (eGFR) <60mL/minute/1.73m2
of body surface area (calculated using the modified
Modification of Diet in Renal Disease study [16] equation),
chronic or acute inflammatory diseases, a history
of neoplastic diseases within 5 years after treatment
termination, and current therapy with DMARDs.
2.2. Study Protocol. Patients were recruited from July 2009
to June 2011. The procedure was carried out in the morning
in the Department of Internal Diseases of the University
Hospital in Krakow. The subjects had been previously asked
to refrain from eating, smoking, and alcohol or caffeine
consumption for at least 12 h. Clinical data including smoking
status, family history of premature CV, coexistent diseases,
and medication were collected according to a prespecified
questionnaire. Blood pressure was measured 3 times on
the left arm after 5 minutes of rest in a sitting position;
values from 2 last readings were averaged. Mean arterial
pressure (MAP) was calculated using the equation: [diastolic
blood pressure + 1/3 (systolic blood pressure − diastolic
blood pressure)]. Anthropometric measurements including
weight, height, and waist circumference were taken and
body mass index (BMI) (body mass [kg]/height [m]2) was
calculated. Then all participants underwent blood sampling
for biochemical assays. The study protocol was approved
by the Bioethical Committee of Jagiellonian University and
written informed consent was obtained from all participants.
2.3. Biochemical Assays. Blood samples were taken from
the left antecubital vein. Serum lipids (total cholesterol
(TC), LDL-cholesterol (LDL-C), HDL-cholesterol (HDL-C),
triglycerides (TG)), and glucose and creatinine levels were
measured with an Hitachi 917 analyzer (Roche Diagnostics,
Hitachi Ltd., Japan) using standardized laboratory tech-
niques. The erythrocyte sedimentation rate (ESR) was deter-
mined in whole blood. High-sensitivity C-reactive protein
(hsCRP) was measured with immunonephelometry (Neph-
elometer BM II, Siemens Healthcare Diagnostics Inc., USA).
Estimated GFR (eGFR) was assessed by the MDRD equation
[16]. Plasma fibrinogen was measured with an BCS analyzer
(Siemens Healthcare Diagnostics Inc., USA).
Plasma for additional biochemical analyses was sepa-
rated and frozen at −70∘C until being assayed. By means
of enzyme-linked immunosorbent assays (ELISA), levels
of cytokines and adhesion molecules were measured: IL-
6 (Human IL-6 Immunoassay Quantikine HS), TNF-𝛼
(Human TNF-𝛼 Immunoassay Quantikine HS), mono-
cyte chemotactic protein-1 (MCP-1) (Human CCL2/MCP-
1 Immunoassay Quantikine), soluble forms of vascular
cell adhesion molecule-1 (sVCAM-1) (Human sVCAM-
1 Immunoassay Quantikine), soluble forms of E-selectin
(sE-selectin) (sE-selectin/CD62E Immunoassay)-(all above:
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R&D Systems, Abingdon, UK), additionally vWf (vWf, Asser-
achrom vWF:Ag)-Diagnostica Stago S.A.S., Asnieres-sur-
Seine, France. Moreover with the use of ELISA, we measured
levels of pentraxin 3 (PTX3) (Human Pentraxin 3/TSG-14
Immunoassay, R&D Systems, Abingdon, UK), osteoprote-
gerin (OPG) (Human Osteoprotegerin ELISA BioVendor,
Brno, Czech Republic), ADMA, symmetric dimethyl-L-
arginine (SDMA) (DLD Diagnostika GmbH, Germany), and
cystatin C (ALLmed Diagnostics). Homocysteine was mea-
sured by high-performance liquid chromatography (HPLC).
In RA patients, rheumatoid factor (RF) was determined
by immunoturbidimetric assay (APTEC Diagnostics nv.,
ALLmed Diagnostics) and anti-cyclic citrullinated pep-
tide antibodies (aCCP) with ELISA (QUANTA Lite CCP
3.1 IgG/IgA ELISA, INOVA Diagnostics, Inc., San Diego,
USA).
2.4. Statistical Analysis. Data are reported as mean (SD) or
median (interquartile range, IQR) unless otherwise indicated.
Proportions were compared using chi-square test or Fisher’s
exact test. The accordance with a normal distribution was
tested by Shapiro-Wilk and Kolmogorov-Smirnov tests. For
intergroup comparisons between control subjects and RA
patients, Student’s 𝑡-test or Mann-Whitney test was used
where appropriate. General Linear Models (GLM) procedure
was used for age-sex adjusted comparisons between the
controls and RA subjects. Homogeneity of variances was
verified by Levene’s test and in appropriate cases,Welch
correction was applied.
GLM were used to test unadjusted and age-sex adjusted
differences between the three groups: non-RA and RA sub-
jects with low and high activity of disease-type III sum of
square was used. The Bonferroni test was performed for post
hoc comparisons. Spearman rank correlations were applied
to test associations between systemic inflammatory markers
(ESR, hsCRP, TNF-𝛼, and IL-6) and biochemical measures
of endothelial activation (vWf, MCP-1, ADMA, sVCAM-1,
sE-selectin, OPG, and PTX3) in either non-RA and or RA
subjects.
Two-tailed 𝑃 values of less than 0.05 were considered
statistically significant. Statistical analysis was performed by
SAS software v. 9.3 (SAS Institute, Cary, NC, USA).
3. Results
Traditional clinical and biochemical CV risk factors are pre-
sented in Table 1. Patients with RA in comparison to control
subjects were older and predominantly female, so the results
were adjusted for age and sex. We observed no significant
differences between RA patients and the control group in
the majority of classical atherosclerosis risk factors (i.e.,
blood pressure, LDL, TG and glucose levels, BMI, and waist
circumference) with the exception of smoking, TC and HDL
levels, and positive family history of premature CVD. In
addition, patients with RA had significantly higher levels of
fibrinogen and cystatin C, lower creatinine, and higher eGFR,
but similar homocysteine concentrations as compared to
control subjects. Looking for the relationship between lipids
and inflammatory markers (ESR, hsCRP, TNF-𝛼, and IL-6)
and between lipids and biochemical measures of endothe-
lial activation (vWf, MCP-1, ADMA, sVCAM-1, sE-selectin,
OPG, and PTX3), we only found positive correlation between
level of total cholesterol and vWF (𝑟 = 0.424, 𝑃 < 0.05),
level of LDL and vWF (𝑟 = 0.453, 𝑃 < 0.05) and negative
correlation between level of total cholesterol and IL-6 (𝑟 =
−0.383, 𝑃 < 0.05).
Biochemical markers of inflammatory activity and
endothelial activation are presented in Table 2. In RA
patients, we observed highly significantly elevated levels
of inflammatory markers. With regard to markers of
endothelial dysfunction/activation, plasma levels of vWf,
sVCAM-1, MCP-1, and PTX3 were significantly increased
in RA patients, whereas differences in the concentrations
of sE-selectin were weakened after the standardization
of the results to gender and age. Similarly, as sE-selectin,
differences in the value of ADMA, ADMA/SDMA ratio
and in concentration of OPG were weakened after the
standardization of the results to gender and age. Looking
for the relationship between systemic inflammatory markers
(ESR, hsCRP, TNF-𝛼, and IL-6) and biochemical measures of
endothelial activation (vWf, MCP-1, ADMA, sVCAM-1, sE-
selectin, OPG, a and PTX3), we found positive correlations
between ESR and vWf (𝑟 = 0.4; 𝑃 < 0.05) and between
hsCRP and sE-selectin (𝑟 = 0.42;𝑃 < 0.05) in RApatients but
not in the control group. Additionally in RA patients OPG
correlated positively with sVCAM-1 (𝑟 = 0.52; 𝑃 < 0.05)
and with sE-selectin (𝑟 = 0.62; 𝑃 < 0.05), in contrast
to control group. Taking into consideration associations
between DAS28 andmentioned above biochemical measures
of endothelial activation, we observed positive correlation
only between DAS28 and levels of vWf (𝑟 = 0.39; 𝑃 < 0.05).
Comparisons of RA patients divided according to disease
activity with the reference to control subjects are presented
in Tables 3 and 4. In RA patients with high disease activity
levels of inflammatory markers (ESR, hsCRP, TNF-𝛼, IL-
6), fibrinogen, sE-selectin, ADMA, and ADMA/SDMA ratio
were significantly higher than in those with a low disease
activity, whereas concentrations of sVCAM-1, vWf, and PTX3
were significantly elevated in RA subjects with a low disease
activity versus control subjects, exhibiting no significant fur-
ther rises in those with a high disease activity. As compared
to the controls, we observed a significant increase in the
concentrations of fibrinogen, ADMA, MCP-1, sE-selectin,
and OPG exclusively in the RA patients with high disease
activity.We observed also lower levels of TC, HDL, and LDL-
C in the group with high disease activity in comparison to
those with low disease activity and control subjects.
4. Discussion
4.1. Biochemical Markers of Endothelial Dysfunction. Patients
with RA of short duration exhibited biochemical indices of
endothelial dysfunction that is highly significantly increased
levels of vWf, MCP-1, and sVCAM-1. This was observed
despite no differences in the majority of classical atheroscle-
rotic risk factors (i.e., blood pressure, TG, LDL-C and glucose
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Table 1: Clinical characteristics and traditional cardiovascular (CV) risk factors of RA patients and control subjects.
RA patients (𝑛 = 29) Control group (𝑛 = 29) P value P adjusteda
Nv Mean (SD) Nv Mean (SD)
Clinical characteristics
Age, years 29 40.96 (9.45) 29 31.65 (7.64) <0.001
Female gender, 𝑛 (%) 29 22 (76%) 29 13 (45%) 0.030
Smoking habit, number (%) 28 12 (43%) 29 5 (17%) 0.045
Positive family history of premature CVD, number (%) 28 15 (54%) 29 6 (21%) 0.013
RF positivity, n (%) 29 25 (86%) — NA
aCCP positivity, 𝑛 (%) 28 24 (83%) — — NA
Disease duration, months 29 12 [4; 18] — — NA
DAS28 29 4.45 (1.53) — — NA
Steroids, number (%) 29 11 (38%) — — NA
NSAIDs, number (%) 29 19 (65%) — — NA
Antihypertensives, number (%) 29 2 (7%) 29 0 0.236
Traditional CV risk factors
Systolic blood pressure, mmHg 29 120.79 (17.95) 28 114.96 (12.78) 0.164 0.872
Diastolic blood pressure, mmHg 29 79.86 (7.72) 28 76.75 (6.76) 0.131 0.825
Mean arterial pressure, mmHg 29 93.5 (10.31) 28 89.48 (7.98) 0.106 0.850
Body mass index, kg/m2 28 23.45 (4.04) 29 23.24 (2.63) 0.909 0.427
Waist circumference (cm) 28 78.6 (10.13) 28 80.67 (10.92) 0.435 0.149
Glucose, mmol/L 29 4.63 (0.4) 29 4.73 (0.46) 0.366 0.142
TC, mmol/L 27 5.01 (1.2) 28 5.03 (0.73) 0.937 0.005
LDL-C, mmol/L 26 3.07 (0.92) 28 2.85 (0.8) 0.366 0.129
HDL-C, mmol/L 26 1.53 (0.42) 28 1.71 (0.49) 0.160 0.018
Triglycerides, mmol/L 26 0.98 (0.47) 28 1.02 (0.54) 0.924 0.450
Creatinine, 𝜇mol/L 29 59.27 (10.08) 29 69.76 (9.67) <0.001 0.008
eGFR, mL/min per 1.73 m2of BSA 29 113.11 (25.19) 29 107.68 (17.23) 0.340 0.009
Fibrinogen, g/L 29 4.03 (1.51) 29 2.98 (0.7) 0.001 0.011
Homocysteine, 𝜇mol/L 29 10.28 (4.62) 27 10.56 (4.33) 0.571 0.804
Cystatin C, mg/L 29 0.72 (0.16) 26 0.53 (0.1) <0.001 <0.001
Data are shown as unadjusted means (SD) or medians [interquartile range, IRQ] or percentages (%). Nv: valid cases; NA: not applicable; RA: rheumatoid
arthritis; RF: rheumatoid factor; aCCP: anti-cyclic citrullinated peptide antibodies; DAS28: disease activity score in 28 joints; NSAIDs: nonsteroidal anti-
inflammatory drugs; CVD: cardiovascular disease; TC: total cholesterol; LDL-C: low-density lipoproteins-cholesterol; HDL-C: high-density lipoproteins-
cholesterol; eGFR: estimated glomerular filtration rate; BSA: body surface area.
aAge-sex adjusted P value for the defining groups of patients in ANOVA (GLMmodels)—type III sum of square (SS) was used.
levels, BMI, and waist circumference) with the exception of
smoking, TC and HDL-C level, and positive family history
of premature CV disease. Increased prevalence of smoking
is of notice in RA group and is undoubtedly a major risk
factor for CV in healthy subjects [17] but also takes part in
pathogenesis of RA [18].On the other hand, it has been shown
that smoking has a smaller impact on the development of
CV diseases in the RA group than in the control group in
long-term observations [4]. Patients with active untreated
RA usually have reduced TC, LDL-C, and HDL-C levels
[19] which is partially consistent with our results. Decreased
levels of cholesterol in active and untreated disease may
be the result of inflammation, as we observed a negative
correlation between total cholesterol and Il-6 in RA patients.
Nevertheless lipids may have paradoxical associations with
the risk of CV diseases in RA, and lower TC and LDL-C
levels are associated with increased CV risk [20]. However,
in our study we observed positive correlation between vWF, a
marker of endothelial dysfunction, and levels of TC and LDL-
C. Additionally, RA patients had elevated cystatin C, whose
emerging role as a marker of atherosclerotic arterial disease
and CV risk has been pointed out [21].We have shown, in our
previous study, that cystatin C is significantly associated with
the probability of pathological thickening of the common
carotid artery wall [22].
4.2. Relations between Inflammatory and EndothelialMarkers.
As proinflammatory cytokines and metabolic abnormalities
associated with systemic inflammation are considered one
of principal mechanisms leading to endothelial dysfunction
in patients with RA [2, 11], we looked for the relationship
between systemic inflammatory markers (ESR, hsCRP, TNF-
𝛼, and IL-6) and biochemical measures of endothelial acti-
vation (vWf, MCP-1, ADMA, sVCAM-1, sE-selectin, OPG,
and PTX3). We found positive correlations between ESR and
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Table 2: Biochemical markers of inflammatory activity and endothelial activation.
RA patients (𝑛 = 29) Control group (𝑛 = 29) P value P adjusteda
Nv Mean (SD) Nv Mean (SD)
ADMA, 𝜇mol/L 29 0.77 (0.2) 28 0.67 (0.18) 0.056 0.154
SDMA, 𝜇mol/L 29 0.56 (0.16) 26 0.62 (0.18) 0.125 0.111
ADMA/SDMA ratio 29 1.46 (0.57) 26 1.17 (0.47) 0.045 0.100
sVCAM-1, ng/mL 29 744.18 (190.08) 28 613.3 (148.4) 0.002 0.048
MCP-1, pg/mL 29 395.8 (249.3) 28 262.4 (90.73) <0.001 0.047
sE-selectin, ng/mL 29 17.65 (8.67) 28 12.45 (8.02) 0.007 0.183
vWf, % 29 109.75 (48.6) 27 73.73 (22.39) <0.001 0.003
Osteoprotegerin, pmol/L 29 5.18 (1.36) 28 4.01 (1.06) <0.001 0.108
Pentraxin-3, ng/mL 29 0.74 (0.29) 28 0.45 (0.17) <0.001 <0.001
ESR, mm/h 28 37.21 (27.44) 29 6.58 (4.79) <0.001 <0.001
hsCRP, mg/L 29 15.26 (24.6) 29 0.84 (0.71) <0.001 0.006
TNF-𝛼, pg/mL 29 2.55 (1.06) 28 1.78 (1.07) <0.001 0.003
Interleukin-6, pg/mL 29 8.48 (8.33) 28 0.86 (0.41) <0.001 0.001
Data are shown as unadjusted means (SD).
Abbreviations: Nv: valid cases; RA: rheumatoid arthritis; ADMA: asymmetric dimethyl-L-arginine; SDMA: symmetric dimethyl-L-arginine; sVCAM-1: soluble
vascular cell adhesion molecule-1; MCP-1: monocyte chemotactic protein-1; sE-selectin: soluble E-selectin; vWF: von Willebrand factor; ESR: erythrocyte
sedimentation rate; hsCRP: high-sensitivity C-reactive protein; TNF-𝛼: tumor necrosis factor-𝛼.
aage-sex adjusted P-value for the defining groups of patients in ANOVA (GLMmodels)—type III Sum of Squares (SS) was used.
‡
𝑃 < 0.05 versus control group, ¥𝑃 < 0.05 versus RA patients with low disease activity in post-hoc analyses for adjusted ANOVA.
vWf and between hsCRP and sE-selectin. Additionally in
RA, we observed rises in OPG and PTX3-novel predictors
of CV disease [23, 24]. The prognostic value of both PTX3
[25] and OPG [26] had been independent of hsCRP, which is
consistent with the lack of correlation with hsCRP also in our
study.However,OPGpotentiates TNF-𝛼-induced endothelial
expression of VCAM-1, intercellular adhesion molecule-1
(ICAM-1), and E-selectin [27], which is in agreement with
our observations, that is positive correlation between OPG
and concentrations of sVCAM-1 and sE-selectin in RA
patients, probably corresponding to endothelial activation.
4.3.Mechanistic Considerations. It is noteworthy that, despite
pronounced rises in hsCRP, TNF-𝛼, and IL-6 in RA patients
with a higher value of DAS28 compared to the remainder,
we observed no significant differences in sVCAM-1, MCP-
1, vWf, PTX3, and OPG, that is, putative markers of local-
ized inflammation and endothelial activation, between sub-
groups of RA patients stratified according to DAS28. These
findings might suggest dissociation of pathways governing
generalized and joint-specific inflammatory reactions from
those responsible for inflammatory activation within the
vascular wall. Accordingly, we observed that a higher disease
activity was not associated with concomitant further rises
in vascular biomarkers (sVCAM-1, vWf, and PTX3). No
significant correlation between DAS28, CRP and ESR, and
serum levels of soluble adhesion molecules, considered as
biomarkers of endothelial cell activation, observed before
or after an anti-TNF-alpha-monoclonal antibody-infliximab
infusion was also found in a series of 34 patients with severe
and active disease (mean DAS28 4.27) undergoing treatment
with this biologic agent [28].
Reports on the association between inflammatory activa-
tion and endothelial dysfunction are inconsistent. Sattar et
al. proposed that increased levels of circulating inflammatory
mediators might cause activation and damage of endothelial
cells in patients with RA [11]. While a positive relationship
between markers of inflammation and endothelial dysfunc-
tion was reported by some authors [8, 12, 29–31], others
showed no associations between endothelial dysfunction and
elevated systemic markers of inflammation both in early [6]
and long-term RA [32]. Sandoo et al. reported that ESR, CRP,
DAS28, and disease durations were unrelated to endothelial
function both in microvascular and in macrovascular beds
[32]. However, we observed positive correlations between
hsCRP and sE-selectin in patients with RA, which may
indicate the connection between systemic inflammation and
endothelial dysfunction, as was shown in another study
[30]. Undoubtedly, non-specific inflammatory markers have
multiple potential detrimental effects on endothelial activa-
tion and dysfunction. C-reactive protein, a well-established
cardiovascular biomarker [33], exerts also an activity by
itself. Besides promoting increased expression of adhesion
molecules (VCAM-1, ICAM-1, and E-selectin) on endothelial
surface, CRP increases monocyte adhesion and migration,
stimulates the synthesis of chemotactic factors (MCP-1),
and induces endothelial secretion of other proinflammatory
factors (NF-𝜅B, IL-6, and IL-8) [34]. BothCRP [35] andTNF-
𝛼 [36] inhibit NO bioavailability. TNF-𝛼 blocks the activation
of endothelial NO synthase (eNOS) by interfering with the
phosphorylation of protein kinaseAkt [37], diminishes eNOS
expression [36], and impedes degradation of ADMA, an
endogenous inhibitor of eNOS [38]. An evidence of the
harmful effects of TNF-𝛼 on endothelium may be a study,
in which it has been shown that different anti-TNF-alpha
drugs have shown to improve endothelial function in RA
6 Mediators of Inflammation
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with severe disease. This improvement was associated with a
decrease of inflammation manifested by reduction of DAS28
and CRP [31, 39].
The crucial role in joint inflammation has been postulated
for TNF-𝛼 [40] and IL-6 [41]. There is some evidence
that the role played by these cytokines in RA pathogenesis
might differ. Dessein and Joffe reported significant reductions
of IL-6 after 2 weeks of high-dose intra-articular methyl-
prednisolone combined with DMARDs, associated with a
decrease in markers of endothelial dysfunction, without sig-
nificant changes in other inflammatory cytokines such as IL-
1 and TNF-𝛼 [42]. The observed discrepancies in the studies
focused on the relationship between endothelial dysfunction
and inflammationmay be in part due to single determination
of these biomarkers without their repeated assays over time
[43].
4.4. Vascular Biomarkers in relation to Disease Activity. The
lack of significant rises in vascular biomarkers (sVCAM-
1, vWf, and PTX3) with increasing disease activity in our
patients with RA may suggest that the presence of RA
itself-rather than the magnitude of concomitant inflamma-
tory activity-underlies endothelial dysfunction. This concept
is in agreement with the results of Vaudo et al., who
observed endothelial dysfunction in young-to-middle-aged
RA patients with long-term disease duration without tradi-
tional CV risk factors, receiving DMARDs, exhibiting a low
disease activity prior to study enrollment [44]. To the best
of our knowledge, our study is the first to show this phe-
nomenon in RA of short duration. Interestingly, according
to our findings, lack of association between flow-mediated
endothelium-dependent vasodilatation and biomarkers of
endothelial dysfunction was also observed in long-standing
RA patients with active disease despite receiving period-
ical anti-TNF-alpha-infliximab therapy [45]. The lack of
significant relation between the majority of inflammatory
markers and endothelial dysfunction may result also from
complex interactions between differentmechanisms involved
in endothelial injury, such as—besides classic cardiovascular
risk factors and chronic inflammation-genetic predisposi-
tion, prooxidative stress, prothrombotic state, and metabolic
abnormalities. Nevertheless, the lack of longitudinal assays in
our cross-sectional study design limits mechanistic interpre-
tation of our results.
On the other hand, it is noteworthy that, in contrast to
other endothelial markers, plasma ADMA and sE-selectin
(correlated positively with hsCRP) were elevated only in
the RA subjects with higher values of DAS28, that may
indicate on their selective association with disease activity.
Nonetheless, previous reports on the topic are inconsistent.
Unlike Kwaśny-Krochin et al. and Sandoo et al. [46, 47], in
the majority of studies, no relationship between ADMA and
DAS28 or CRP levels in RA was found [48–52]. Although
both Kwaśny-Krochin and Sandoo revealed significant pos-
itive correlations between CRP, DAS28, and ADMA, in
contrast to our study, they examined the patients with long-
lasting RA (respectively mean 8.1 and 7.6 years).
A possible mechanism linking increased ADMA with
the presence of inflammation can be a reduced activity of
dimethylarginine dimethylaminohydrolase (DDAH) due to
elevated TNF-𝛼. Accordingly, a decrease in ADMA levels
might be expected to accompany a fall in disease activity;
nevertheless, reports on early RA patients provided con-
flicting results. Although Di Franco et al. observed sig-
nificant decreases in both DAS28 and ADMA level after
antirheumatic treatment [52], others have demonstrated
no drops in ADMA concentrations in spite of a reduc-
tion of disease activity in response to DMARDs, including
TNF-𝛼 antagonists [47, 53]. The inconsistency is suggestive
of the notion of a complex net of pathways underlying
increased ADMA levels such as decreased expression of
DDAH [38] and overexpression of protein arginine type I
𝑁-methyltransferases in the presence of enhanced oxidative
stress and hypoxia in the inflamed synovium [54], as well as
possibly increased endothelial cell turnover and the conse-
quent liberation of free ADMA during protein catabolism [5,
55], known to be potentiated in insulin-resistant states [56].
As Dimitroulas et al. have recently described an association
between ADMA and insulin resistance in RA [57], elevated
ADMA in RA subjects with high disease activity can impair
glucose homeostasiswith subsequent prognostic effects, anal-
ogously to the predictive value of ADMA in future decline of
glucose tolerance in stable coronary artery disease [58]. On
the other hand, a recent study showed a negative correlation
between ADMA levels and total cholesterol and LDL-C in
a series of patients with ankylosing spondylitis undergoing
period anti-TNF-alpha-monoclonal antibody therapy that at
the time of the study had low disease activity [59]. Despite
significantly lower levels of total and HDL cholesterol and
higher levels of ADMA observed in our RA patients and
considering contradictory associations of lipids with the risk
of CV diseases in RA, we found no correlation between
ADMA and cholesterol in the present study.
4.5. Study Limitations. Our study has some limitations. First
of all our conclusions are constrained by low number of
study participants and a cross-sectional design of the study.
It makes impossible to follow changes in the relationship
between markers of inflammation and endothelial dysfunc-
tion in the course of disease. The recruitment of a large
group of newly diagnosed RA subjects without DMARDs has
been proven difficult; thus, our results should be confirmed
in multicenter prospective study. Additionally, significant
intergroup differences in age and sex pose another limitation
although we adjusted the results for age and gender. In
addition, endothelial function was assessed only by serum
biomarkers; further studies including different techniques are
warranted.
5. Conclusions
In summary, our study shows differential associations of
inflammatory and endothelial biomarkers with disease activ-
ity in RA of short duration. Higher levels of ADMA and
sE-selectin observed in patients with high disease activity,
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contrary to those with low disease activity, may point out the
relationship between the severity of inflammatory response
and endothelial dysfunction. However, higher levels of vWf,
MCP-1, and sVCAM-1 observed in patients with low disease
activity exhibiting no further significant riseswith an increase
in disease activity may suggest a dissociation of pathways
governing generalized and joint-specific inflammatory reac-
tions from those responsible for endothelial activation and
chronic inflammation within the vascular wall and that the
presence of RA itself, rather than the magnitude of con-
comitant inflammatory activity, contributes to endothelial
dysfunction.
The endothelial dysfunction indicates increased risk of
atherosclerosis despite early stage of RA. Together with
elevated levels of fibrinogen and cystatin C-recognized as
markers of CV risk, we found higher concentrations of PTX3
and OPG-novel biomarkers of endothelial activation and
predictors of CV disease. Hence, OPG and PTX3 appear that
they may be added to biomarkers of vascular involvement in
RA of short duration. Due to limitations of our study, the
conclusions require further longitudinal studies to identify
endothelial markers relevant for future cardiovascular mor-
bidity in RA.
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Filloy, M. T. Garćıa-Unzueta, and J. Llorca, “Lack of association
between flow-mediated endothelium-dependent vasodilatation
and biomarkers of endothelial dysfunction in patients with
severe rheumatoid arthritis,” Rheumatology International, vol.
32, no. 12, pp. 4071–4072, 2012.
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